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Antineutrophil cytoplasmic autoantibody (ANCA)-associated
small-vessel vasculitis frequently affects the kidney. Here we
describe the rates of infection, disease relapse, and death in
patients with ANCA small-vessel vasculitis before and after
end-stage renal disease (ESRD) in an inception cohort study
and compare them to those of patients with preserved renal
function. All patients had biopsy-proven ANCA small-vessel
vasculitis. Fisher’s exact tests and Wilcoxon rank sum tests
were used to compare the characteristics by ESRD status.
ESRD follow-up included time on dialysis with transplants
censored. Over a median follow-up time of 40 months, 136 of
523 patients reached ESRD. ESRD was associated with
new-onset ANCA small-vessel vasculitis in 51% of patients,
progressive chronic kidney disease without active vasculitis
in 43%, and renal relapse in 6% of patients. Relapse rates of
ANCA small-vessel vasculitis, reported as episodes/
person-year, were significantly lower on chronic dialysis (0.08
episodes) compared with the rate of the same patients
before ESRD (0.20 episodes) or with patients with preserved
renal function (0.16 episodes). Infections were almost twice
as frequent among patients with ESRD on maintenance
immunosuppressants and were an important cause of death.
Given the lower risk of relapse and higher risk of infection
and death, we suggest that immunosuppression be geared
to patients with ESRD who present with active vasculitis.
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Antineutrophil cytoplasmic autoantibody-associated small-
vessel vasculitis (ANCA-SVV) frequently affects the kidneys,
causing a destructive pauci-immune necrotizing and cres-
centic glomerulonephritis. Despite improved therapies and
outcomes,1–4 ANCA-SVV still results in end-stage renal
disease (ESRD) in a quarter of patients over 3–4 years.3,5,6
Information on the course of ANCA-SVV while on chronic
dialysis is relatively scant. Risk factors for relapse have been
described for patients with ANCA-SVV,3 but it is not clear
whether they apply to the prediction of relapse after ESRD is
reached. Knowledge about risk and severity of relapse is
crucial in determining the need for maintenance immuno-
suppression. This is of particular importance as the rate of
infections is significantly higher among patients on dialysis.7
Chronic dialysis may result in a relative quiescence of the
autoimmune process.8–11 It has thus been reported that the
relapse rate of ANCA-SVV among patients on chronic
dialysis is substantially lower compared with that among
patients with preserved renal function.7,12 It is not clear
whether this reduced rate of relapse is attributable to
continued immunosuppression or simply reflects the natural
progression of this disease. Fear of disease relapse has led to
the use of preventive maintenance immunosuppressive
therapy irrespective of the need for dialysis.7,13 However,
morbidity associated with dialysis demands that any benefit
from immunosuppression outweighs the risks. If ANCA-SVV
disease activity and relapses decrease on chronic dialysis,
prolongation of immunosuppression after ESRD may be
associated with more risk than benefit.
On the basis of a large inception observational cohort of
patients with ANCA-SVV, we describe the clinical course of
dialysis-dependent patients compared to patients with
preserved renal function with respect to the cause of ESRD,
the disease activity, frequency of relapse, morbidity, and
mortality.
RESULTS
Description of the ANCA-SVV ESRD and non-ESRD groups
Of the 523 ANCA-positive patients with biopsy-proven
ANCA-SVV in our registry, 95 needed dialysis at initial
presentation. Of these, 40 remained dialysis dependent or
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died during the first 3 months, and 55 recovered enough
renal function to discontinue dialysis. As of 1 October 2007,
we identified 136 patients who had reached ESRD (ESRD
group) and 387 patients with preserved renal function (non-
ESRD group). No clinical information after the start of
dialysis was available for 43 patients in the ESRD group;
therefore, they were excluded from the analyses. Likewise, 28
patients (7%) with preserved renal function were excluded
because of limited follow-up (recently diagnosed cases or lost
to follow-up) (Figure 1). The median observation time for
the ESRD group, including time after ESRD, was 63 months
(interquartile range (IQR): 13–75 months) and for the non-
ESRD group was 40 months (IQR: 15–55 months).
Demographics
As shown in Table 1, demographics, and baseline and disease-
related characteristics of the total ESRD group (n¼ 136) were
similar to those of the ESRD group with available follow-up
(n¼ 93). As a consequence, we considered the latter group
representative of the total ESRD group and based estimates
and comparisons on this subgroup.
All patients in the ESRD group and 87% in the non-ESRD
group had biopsy-proven glomerulonephritis. No significant
differences were observed in the distribution of gender and
race, with a predominance of Caucasians in both groups (84
and 87%, respectively). Mean age at diagnosis of ANCA-SVV
was 56 years in both groups.
In the ESRD group, mean age at initiation of chronic
dialysis was 58 years. Over the follow-up time with renal
failure, the majority of patients received hemodialysis (n¼ 83
and 89%), whereas only a minority were treated at any time
with peritoneal dialysis (n¼ 31 and 33%) or had a kidney
transplant (n¼ 19 and 20%).
Characteristics related to ANCA-SVV
The mean Birmingham Vasculitis Activity Score14 (BVAS) at
initiation of chronic dialysis was 7.75±8.05, whereas 51.5%
of the patients had active disease in at least one organ
(BVAS41). All patients in the ESRD group (n¼ 136) were
further categorized with respect to the phase of ANCA-SVV,
which led to ESRD (Table 2). Sixty-nine patients (51%)
reached ESRD due to new-onset ANCA glomerulonephritis
(BVAS¼ 13.76±5.98), with 51 dialysis dependent at pre-
sentation and 12 who progressed to renal failure without
attaining a remission. Of the 51 patients who required
dialysis at presentation, 7 were not treated, whereas the
remaining 44 received immunosuppressive therapy. Relapsing
disease involving the kidney led to ESRD in eight cases (6%)
(BVAS¼ 7.50±5.92). Fifty-eight patients (43%) reached
ESRD due to progressive chronic kidney disease without
evidence of active ANCA glomerulonephritis (BVAS¼ 0)
(Tables 1 and 2). Mean time from diagnosis to ESRD in these
patients was 24 months (IQR: 12–45 months).
ANCA-SVV
(biopsy proven + ANCA 
positive) n =523  
All ANCA-SVV/ESRD
n =136  
All non-ESRD
n =387  
Excluded: Patients with
no follow-up
after ESRD: n =43
Excluded: Patients with 
inadequate
information: n =28 
ANCA-SVV/ESRD
n =93  
Non-ESRD
n =359
Figure 1 | Inception cohort with ANCA vasculitis.
Table 1 | Characteristics of patients with ANCA-SVV who
reached ESRD
Characteristic
All ANCA-
SVV/ESRD
ANCA-SVV/ESRD with available
long-term information
n (%) or mean±s.d. n=136 n=93
Age at diagnosis (years)
(±s.d.)
57±21 56±22
Gender, female (%) 67 (49%) 47 (51%)
Race
Caucasian 113 (83%) 78 (84%)
Other 23 (17%) 15 (16%)
ANCA typea
PR3 or C-ANCA 45 (34%) 35 (39%)
MPO- or P-ANCA 88 (66%) 55 (61%)
Disease category
WG 19 (14%) 14 (15%)
MPA 67 (49%) 48 (52%)
RL 49 (36%) 30 (32%)
CSS 1 (1%) 1 (1%)
Organ involvement, ever
Lung 63 (46%) 47 (51%)
ENT 36 (27%) 26 (28%)
Initial treatmentb
No treatment 12 (9%) 6 (7%)
Corticosteroids alone 23 (17%) 13 (14%)
Prednisone + CYC 96 (72%) 70 (77%)
Other 2 (2%) 2 (2%)
Age at initiation of
ESRD (years)
58±21 57±22
Duration of disease,#
months (±s.d.)
16.6±27.01 16.9±28.8
Median 3.45 2.4
IQR 0.03, 24.01 0.0, 24.01
BVAS at diagnosis of
ESRD (±s.d.)
7.75±8.05 8.21±8.25
ANCA-SVV, antineutrophil cytoplasmic autoantibody-associated small-vessel vascu-
litis; BVAS, Birmingham Vasculitis Activity Score; CSS, Churg–Strauss syndrome; CYC,
cyclophosphamide; ENT, ear, nose, and throat; ESRD, end-stage renal disease; MPA,
microscopic polyangiitis; RL, renal-limited disease; WG, Wegener’s granulomatosis.
#Duration of disease before ESRD among patients who reached ESRD and for the full
duration of follow-up for the non-ESRD group.
aThree patients were reported as ‘ANCA positive,’ but had missing information on
ANCA specificity. These three patients were among those with long-term follow-up
information.
bThree patients had missing information on initial treatment, two of whom were
among those with long-term follow-up information.
Kidney International (2009) 76, 644–651 645
S Lionaki et al.: Clinical course of ANCA small-vessel vasculitis on chronic dialysis o r ig ina l a r t i c l e
Myeloperoxidase ANCA (MPO-ANCA) was more fre-
quent in the ESRD group (61%) than in the non-ESRD
group (53%), but this difference was not statistically
significant (P¼ 0.25). The ESRD group comprised a higher
proportion of patients with renal-limited disease (33%) and a
lower proportion of patients with Wegener’s granulomatosis
(15%) compared with the non-ESRD group (20 and 27%,
respectively; P¼ 0.0104) (Table 3). A total of 66 ESRD
patients (71%) had at least one risk factor previously
associated with relapse in a subset of the overall cohort3
(PR3-ANCA positive, pulmonary or upper respiratory
involvement), which was similar to the overall group where
274 (76%) had at least one of these risk factors.
Regarding organ involvement, all patients within the
ESRD group and 94% of patients in the non-ESRD group
exhibited kidney involvement at some point, but entry serum
creatinine was significantly higher in the ESRD group
(Po0.0001). Lung involvement was present with similar
frequency, whereas upper respiratory tract involvement was
more frequent among the non-ESRD patients.
Compared with the non-ESRD group, more patients in
the ESRD group received no immunosuppression (6 versus
2%) and corticosteroids alone (14 versus 8%), whereas fewer
Table 3 | Comparison of the ANCA-SVV ESRD and non-ESRD groups
Characteristica ANCA-SVV ESRD ANCA-SVV non-ESRD
n (%), mean±s.d., rate with 95% CI, or median and IQR, as noted n=93 n=359 P-value
Age at diagnosis (years) 56±22 56±18 0.32
Gender, female (%) 47 (51%) 164 (46%) 0.53
Race
Caucasian 78 (84%) 312 (87%) 0.80
Non-Caucasian 15 (16%) 47 (13%)
ANCA type
PR3 or C-ANCA 35 (39%) 164 (47%) 0.25
MPO- or P-ANCA 55 (61%) 188 (53%)
Disease category
WG 14 (15%) 97 (27%) 0.0104
MPA 48 (52%) 187 (53%)
RL 30 (33%) 72 (20%)
Organ involvement
Kidney 93 (100%) 339 (94%) 0.0193
Lung 47 (51%) 187 (52%) 0.82
ENT 26 (28%) 143 (40%) 0.04
Peak serum creatinine at onset (±s.d.) (mg per 100ml) 6.9±4.5 3.7±2.8 o0.0001
Initial treatment
No treatment 6 (6%) 8 (2%) 0.007
Corticosteroids alone 13 (14%) 29 (8%)
Prednisone + CYC 70 (77%) 300 (84%)
Other 2 (2%) 22 (6%)
Treatments with CYC, months 6.6±7.5 9.1±9.4 0.0002
Treatment resistant 52 (56%) 29 (8%) o.0001
ANCA-SVV pre-ESRD 0.20 (0.13–0.26) 0.16 (0.13–0.17) 0.20
Relapse rate, episodes per person-year (95% post-ESRD CI) 0.08 (0.04–0.11) NA
P-value versus pre-ESRD=0.0012
Malignancy rate, episodes per person-year (95% CI) 0.04 (0.01–0.07) 0.01 (0.007–0.02) 0.046
Patients with malignancy 5 (5%) 15 (4%)
Total number of malignancies 8 15
Mortality rate (deaths/person-year) 0.31 (0.26–0.36) 0.07 (0.05–0.08) o0.0001
Deaths, total number (%) 59 (63%) 76 (21%)
Median follow-up time in months (IQR) 63 (13–75) 40 (15–55)
ANCA-SVV, antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis; BVAS, Birmingham Vasculitis Activity Score; CI, confidence interval; CSS, Churg–Strauss
syndrome; CYC, cyclophosphamide; ENT, ear, nose, and throat; ESRD, end-stage renal disease; IQR, interquartile range (25th and 75th percentile); MPA, microscopic
polyangiitis; NA, not applicable; RL, renal limited disease; WG, Wegener’s granulomatosis.
aOne to three values were missing for each variable and were excluded from estimates and comparison tests.
Table 2 | Summary of cause and disease activity among
patients reaching ESRD
ESRD subgroup n (%)
% With active
disease
BVAS
(mean±s.d.)
ESRD groupa 136 51.5 7.75±8.05
New-onset GN 69 (51%) 100 13.76±5.98
Relapsing GN 8 (6%) 100 7.50±5.92
Progressive CKD without
active vasculitis
58 (43%) 0 0
BVAS, Birmingham Vasculitis Activity Score; CKD, chronic kidney disease; ESRD, end-
stage renal disease; GN, glomerulonephritis.
aOne unknown ESRD cause.
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in the ESRD group received treatment with combined
therapy with corticosteroids and cyclophosphamide (CYC)
(75 versus 84%) either orally or intravenously at the time of
diagnosis (P¼ 0.007) (Table 3). Patients in the ESRD group
received CYC for a shorter duration (6.6±7.5 months) than
did patients in the non-ESRD group (9.1±9.4 months,
P¼ 0.0002). Treatment resistance was more common in the
ESRD group (56%) than in the non-ESRD group (8%;
Po0.0001).
Among the ESRD patients, we compared those who
required dialysis within 1 month of diagnosis of ANCA-SVV
with the patients who reached ESRD later, as a result of
relapse or a progressive decline in glomerular filtration rate
without active vasculitis or glomerulonephritis (Table 4).
Patients with ESRD from new-onset ANCA glomerulone-
phritis had higher levels of serum creatinine (8.6±4.2 versus
5.3±3.5 mg per 100 ml, Po0.0001), received treatment with
CYC for a shorter period (2.9±3.0 versus 8.4±7.9 months,
Po0.0001), and were more frequently resistant to therapy
(86 versus 25%, Po0.0001) (Table 4).
Relapse rates of ANCA-SVV before and after ESRD
Relapse rates of ANCA-SVV were estimated before and after
initiation of chronic dialysis, and for the non-ESRD group. In
the ESRD group, relapses occurred at a rate of 0.20 episodes
per person-year (95% confidence interval (CI): 0.13–0.26)
before dialysis, which was similar to the rate of 0.16 episodes
per person-year (95% CI: 0.13–0.17) for the non-ESRD group
(P¼ 0.20). When the non-ESRD group was limited to only
patients with renal involvement (n¼ 339), the relapse rate was
similar (0.15 episodes per person-year; 95% CI: 0.14–0.17).
Post ESRD, the relapse rate was 0.08 per person-year (95% CI:
0.04–0.11), which was significantly lower than the pre-ESRD
rate (P¼ 0.0012) (Table 3). Similarly, the exclusion of patients
with renal-limited ANCA-SVV did not significantly impact the
relapse rate in the non-ESRD group (0.17 episodes per person-
year; 95% CI: 0.15–0.19) or the relapse rates before and after
ESRD (0.20 and 0.08 episodes per person-year, respectively) in
the ESRD group.
Among patients who reached ESRD, the relapse rate pre
and post ESRD was calculated separately for the subgroups of
patients with PR3- and MPO-ANCA (Table 5). For patients
with PR3-ANCA, the rate of relapse decreased significantly
from 0.34 (95% CI: 0.25, 0.42) episodes per person-year pre
ESRD to 0.11 (95% CI: 0.04, 0.18) post ESRD (P¼ 0.0015).
For patients with MPO-ANCA, the rates of relapse were low
and did not change significantly pre and post ESRD (0.06
(95% CI: 0.004, 0.12) and 0.04 (95% CI: 0.002, 0.076),
respectively (P¼ 0.47)).
Ten (11%) patients experienced 14 vasculitis relapses after
the start of dialysis corresponding to an incidence rate of 0.25
relapses per patient-year (95% CI: 0.17, 0.33). These 10
patients had had a total of eight relapses pre ESRD (0.40
relapses per patient-year (95% CI: 0.26, 0.53)). Three of them
had ESRD due to new-onset vasculitis, one due to relapse,
and six due to chronic kidney damage. Five of the 14 post-
ESRD relapses occurred while the patients were on main-
tenance immunosuppressive therapy. Organ systems affected
by relapses included the lungs (n¼ 8), upper respiratory tract
(n¼ 3), skin (n¼ 2), musculoskeletal system (n¼ 3), and the
eye (n¼ 1). The mean BVAS at relapse was 8.9, excluding
three cases for which insufficient information was available
for scoring. Immunosuppressive treatment was instituted in
11 of 14 occurrences. Of the three untreated patients, one had
unrecognized active vasculitis that was detected on autopsy
and one had upper respiratory tract disease managed with a
local procedure. The third was an elderly patient with only
mild skin manifestations. Relapse outcomes included com-
plete or partial remission in eight patients, death in five
(including the relapse detected at autopsy), and an unknown
outcome in one patient.
Adverse events
Three hundred and fifty-four episodes of infections occurred
in 61 patients on chronic dialysis corresponding to an
incidence rate of 1.92 episodes per person-year. Infectious
Table 4 | Characteristics of the patients with ANCA-SVV and
ESRD in association with phase of ANCA glomerulonephritis
that led to chronic renal failure
ANCA-SVV/ESRD, n=136
New-onset
disease,
n=69a
Relapse or
CKD, n=66a P-value
Peak entry creatinine (±s.d.) 8.6±4.2 5.3±3.5 o0.0001
Treatment with CYC,
months (±s.d.)
2.9±3.0 8.4±7.9 o0.0001
Treatment resistant (%) 59 (86%) 16 (25%)b o0.0001
Median time from ANCA-SVV
diagnosis to ESRD in months,
median (IQR)
0.03 (0–0.9) 24 (10–39) o0.0001
ANCA-SVV, antineutrophil cytoplasmic autoantibody-associated small-vessel vascu-
litis; CYC, cyclophosphamide; ESRD, end-stage renal disease; IQR, interquartile range.
a One patient with unknown disease status when reached ESRD.
b Two missing values for treatment resistance.
Table 5 | Summary of pre and post relapses in patients who
reached ESRD
ESRD Group n (%)
n
(relapse)
Follow-up
time
(years)
Incidence
(per
patient-
year) 95% CI
Pre
ESRD 93 26 130.4 0.20 (0.13, 0.26)
PR3-ANCAa 35 (39%) 22 65.3 0.34 (0.25, 0.42)
MPO-
ANCAa
55 (61%) 4 62.4 0.06 (0.004, 0.12)
Post
ESRD 93 14 184.6 0.08 (0.04, 0.11)
PR3-ANCAa 35 (39%) 7 65.6 0.11 (0.04, 0.18)
MPO-
ANCAa
55 (61%) 4 101.1 0.04 (0.002, 0.076)
CI, confidence interval; ESRD, end-stage renal disease.
aData on ANCA antigen specificity missing for 3 of the 93 patients who reached
ESRD.
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episodes included the respiratory and urinary tracts, the skin,
dialysis access sites, bacteremia of unknown origin, and
peritonitis. The rate of infection was significantly higher
among immunosuppressed patients (1.94 episodes per
person-year; 95% CI: 1.61–2.26) than among those not
receiving immunosuppressive therapy (1.03 episodes per
person-year; 95% CI: 0.87, 1.19; Po0.0001).
Eight malignancies were diagnosed in five patients in the
ESRD group, resulting in an incidence rate of 0.04 episodes
per patient-year (95% CI: 0.01–0.07), which was statistically
higher than that in the non-ESRD group where 15
malignancies were found in 15 patients, resulting in a rate
of 0.01 episodes per person-year (95% CI: 0.007–0.02,
P¼ 0.046) (Table 3).
Mortality rate and patient survival before and after ESRD
In the ESRD group, 59 deaths occurred, corresponding to a
mortality rate of 0.31 deaths per person-year (95% CI:
0.26–0.36). Deaths occurred in a median of 43 months from
diagnosis of ANCA-SVV and 37 months from the start of
chronic dialysis. Causes of death were known in 21 of the
ESRD cases, and were attributed to infection (n¼ 9), active
vasculitis (n¼ 5), cardiovascular disease (n¼ 3), malignancy
(n¼ 3), and withdrawal from dialysis (n¼ 1). Within a
month of diagnosis, the predominant cause of death was
active vasculitis (4 of 5 deaths), whereas subsequent deaths
were primarily due to infections (8 of 16 deaths). Death rate
among patients who reached ESRD with active vasculitis
(new-onset disease or relapse) (37 of 56, 66%) was similar
compared with those who reached ESRD with no active
vasculitis (22 of 37, 60%, P¼ 0.66). However, the incidence
of death among patients with ESRD from new-onset disease
(0.86 deaths per patient-year; 95% CI: 0.70, 1.01) was
significantly higher than that for those who reached ESRD
later (0.16 deaths per patient-year; 95% CI: 0.12, 0.21)
corresponding to an incidence ratio of 5.22 (95% CI: 3.79,
7.21). One-year and 5-year survival rates were 77 and 28%,
respectively, for the ESRD group (from disease onset). The
proportion of patients with ESRD who died was similar for
the three disease categories (63% of patients with either
renal-limited disease or microscopic polyangiitis, 65% of
patients with Wegener’s granulomatosis).
In the non-ESRD group, 76 deaths occurred correspond-
ing to a significantly lower mortality rate (0.07 deaths per
person-year; 95% CI: 0.05–0.08; Po0.0001) than in the ESRD
group (0.27, 95% CI: 0.21–0.32 per person-year). Cause of
death was unknown in 55 patients. In the 21 with known
causes, death was attributed to vasculitis (n¼ 7), cardiovas-
cular disease (n¼ 6), malignancy (n¼ 5), and infections
(n¼ 3). One-year and 5-year survival rates were 92 and 71%,
respectively.
DISCUSSION
Despite the improved therapy of ANCA-SVV over the past 2
decades, the frequency of ESRD remains elevated. In our
patient population, 26% of patients reached ESRD over a
median of 34 months (IQR: 12–75 months). It is noteworthy
that 94% of patients who reached ESRD did so in one of two
settings: presentation with advanced renal failure requiring
dialysis at or near the time of diagnosis, or progression to
ESRD without evidence of active glomerulonephritis or
vasculitis over a median of 24 months. Eighty percent of
patients who required dialysis near diagnosis presented with
severe renal insufficiency (mean entry serum creatinine of
8.6 mg per 100 ml) and remained dialysis dependent despite
the institution of appropriate immunotherapy with corticos-
teroids and CYC. This underscores the importance of early
diagnosis and prompt treatment to attain recovery of renal
function before renal scarring has occurred. It is worth noting
that the majority of patients presented before plasmapheresis
was used routinely for patients presenting with advanced
renal disease,15 which may decrease the frequency of
irreversible dialysis dependence in the future.
In our cohort, there was a higher representation of
patients with renal-limited disease in the dialysis-dependent
group compared with that in the non-ESRD group. In the
absence of extrarenal manifestation of disease, patients may
not seek medical attention until they develop uremic
symptoms associated with advanced renal scarring and a
limited chance of recovery. This concept is supported by our
finding that patients who require dialysis at or near diagnosis
presented with significantly higher serum creatinine levels. It
is also supported by previous correlations of poor renal
prognosis with histological markers of chronic scarring.3,16,17
Comparison of initial therapy between the ESRD and
non-ESRD groups reveals a higher frequency of patients who
did not receive immunosuppressive therapy, and a shorter
duration of treatment with CYC in the dialysis-dependent
group. The higher frequency of non-treated patients reflects
the perception that, in patients with advanced renal failure
and no extrarenal vasculitis, the risk of immunosuppressive
therapy outweighs the potential benefit. However, a recent
cohort analysis showed that there was no glomerular
filtration rate below which treatment was futile.3 Similarly,
a subgroup analysis of patients presenting with advanced
renal failure participating in the MEPEX study revealed that
therapeutic futility is seen only when 2% or fewer of
glomeruli are normal.4
The finding of a shorter initial course of CYC among the
ESRD group is a result rather than a cause of dialysis
dependence. In the absence of extrarenal manifestations,
cytotoxic therapy is usually discontinued when dialysis
dependence continues beyond 3 months. Renal function is
not likely to recover beyond that point,6,18–20 whereas
continuing cytotoxic therapy is associated with serious
infections and death.20
An important issue to address is whether dialysis-
dependent patients should receive maintenance immuno-
suppression for relapse prevention. This decision should be
based on an assessment of the risk of continued immuno-
suppression relative to that of relapse. In our cohort, patients
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with ESRD had a significantly lower relapse rate after the
start of dialysis (0.08 episodes per person-year) than that
before (0.20 episodes per person-year). Differences in relapse
rates between those on dialysis and those pre dialysis have
also been reported by Weidanz et al.7, with a rate after dialysis
of 0.13 per person-year (95% CI: 0.07, 0.19) and before
dialysis of 0.40 per person-year (95% CI: 0.15, 0.98). This
lower rate on dialysis reflects only extrarenal relapses, as
recurrent or persistent glomerulonephritis is essentially
undetectable once ESRD is reached. It may also reflect
changes of the autoimmune response in ESRD, as has been
suggested for systemic lupus erythematosus.8–11 Our relapse
rate among patients with ESRD is similar to that reported in
other cohorts (0.0912 and 0.137 per person-year), but
substantially lower than that reported by Haubitz et al.13
(0.24 per person-year) among 35 patients with Wegener’s
granulomatosis who reached ESRD.
The lower rate of relapse after ESRD occurs in the
context of a high rate of infections, especially among
patients on maintenance immunosuppressants, whose rate
was almost twice that of patients not receiving such
treatments. Although the total number of vasculitic flares
in our ESRD group was too small (14 events in 10 patients)
to formally assess the effect of maintenance immunosuppres-
sion on relapse, our findings suggest that the risks of
maintenance immunosuppression outweigh the potential
benefit among patients with ESRD. We contend that
immunosuppressive therapy should be restricted to patients
with clinical evidence of active extrarenal manifestation
of vasculitis.
The 1-year survival rate of 77% for patients in the ESRD
group is comparable with rates of 64–83% reported in other
cohorts.5–7,7,12,13 In our cohort, the survival rates were over
four times worse in the ESRD group compared with those in
the non-ESRD group, which is similar to previous reports.6
The 1-year and 5-year survival rates for patients with ANCA-
SVV and ESRD (77 and 28%, respectively) are also
considerably worse compared with survival rates for adult
patients with ESRD from all causes (90 and 48%, respec-
tively).21 The excess mortality among ANCA-SVV ESRD
patients is likely attributable to a combination of sequelae of
systemic vasculitis, long-term effects of therapy with
corticosteroids, CYC and other immunosuppressants, and
older age. The significantly higher incidence of death among
the patients with ESRD from new-onset disease compared
with that of patients reaching ESRD late in their course of
disease likely reflects early deaths from severe active vasculitis.
One may argue that a limitation of this study pertains to
the composition of our cohort of patients with ANCA-SVV
with a large predominance of patients with glomerulone-
phritis, which may reflect a lower rate of relapse. However, it
is unlikely that the small number of disease flares after ESRD
were due to an over-representation of patients at low risk (for
example, patients with renal-limited disease) as 71% had at
least one risk factor of relapse (50% with lung involvement,
28% with upper respiratory tract disease, and 39% PR3-
ANCA positive). In addition, the significant decrease in the
rate of relapse post ESRD we observed is not due to an over-
representation of patients with MPO-ANCA among patients
with ESRD, as this decrease in relapse rate was primarily seen
among patients with PR3-ANCA. Furthermore, we report a
sharp decrease in the rate of relapses after ESRD (compared
with that before) based on the same population, which
excludes any effect of the cohort composition on the relapse
rate post ESRD. Unfortunately, the small number of disease
flares does not allow assessment of the influence of these
three risk factors on relapse in the population of patients with
ESRD.
Other limitations to our study include retrospective BVAS
scoring, incomplete data on the causes of death, and possibly
incomplete reporting of serious infections. The latter,
however, would result in an underestimation of the
importance of infections in the outcome of patients with
ANCA vasculitis and ESRD. For lack of suitable local or
regional data, we were also unfortunately unable to compare
the all-cause and cardiovascular mortality of patients with
ANCA vasculitis and ESRD with that of a control population
of patients with ESRD, controlling for age and race.
In summary, despite advances in treatment, a quarter of
patients with ANCA-SVV still suffer from ESRD. ESRD is
largely contributed to by new-onset disease with severe renal
failure, rather than by persistent or relapsing vasculitis,
underscoring the need for prompt diagnosis and therapy.
Faster recognition of ANCA-SVV and implementation of a
more effective therapy may help reduce the burden of ESRD.
Patients with ANCA-SVV and ESRD experience a low rate of
relapses, but are at high risk of infectious complications
associated with significant morbidity and mortality. These
observations support the judicious use of immunosuppres-
sion in patients with ANCA-SVV ESRD, with restriction to
use only in the setting of active vasculitis.
MATERIALS AND METHODS
Description of patient population and definitions
Patients enrolled in the ANCA-SVV registry as of 1 October 2007
were eligible to be included in this inception cohort study, which
was started in 1986. Registry patients were identified at or near
initial diagnosis and fulfilled three criteria: native kidney biopsy
showing pauci-immune ANCA glomerulonephritis with or without
granulomatous inflammation and/or biopsy on any other tissue
showing pauci-immune SVV (n¼ 27; predominantly the lung,
sinus, and skin), positive ANCA determination by immunofluores-
cence microscopy or antigen-specific enzyme-linked immunosor-
bent assay,22 and signed informed consent for review of medical
records. ANCA positivity was further classified as cytoplasmic
ANCA and/or anti-proteinase-3 (anti-PR3) ANCA, or perinuclear
ANCA and/or anti-myeloperoxidase ANCA (anti-MPO) or both. A
perinuclear ANCA alone required a concurrent negative antinuclear
antibody test.23,24 Renal biopsy specimens were evaluated by the
University of North Carolina Nephropathology Laboratory and
patients were followed by physicians of the Glomerular Disease
Collaborative Network. The Glomerular Disease Collaborative
Network and subsets of the ANCA-SVV registry have previously
been described elsewhere.3,18,19
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Diagnostic ANCA-SVV categories were defined according to the
Chapel Hill Consensus Conference.23 A diagnosis of Wegener’s
granulomatosis was defined by the presence of necrotizing
granulomatous inflammation in any tissue by histology, and/or
imaging showing pulmonary nodules or cavities (non-infectious)
and/or bony erosions, and/or subglottic stenosis in the upper
respiratory tract. Churg–Strauss syndrome was defined by the
presence of asthma, eosinophilia, and necrotizing granulomatous
inflammation. Microscopic polyangiitis was defined by systemic
necrotizing SVV without evidence of granulomatous inflammation
or asthma.23,25
Organ involvement was defined by biopsy or by previously
described criteria.18,19 BVASs were determined from a review of
medical records. Treatment categories were determined by the
regimen used at diagnosis and included no therapy, corticosteroids
alone, or corticosteroids in combination with CYC or other
immunosuppressive therapies.3,18 Duration of immunosuppressive
therapy was recorded but patients were considered as treated with a
given regimen independent of duration.
Outcomes of interest included treatment resistance, remission on
or off therapy, relapse, ESRD, and death, as previously described.3,18
In brief, outcomes after the initial diagnosis of ANCA-SVV were
determined as treatment resistance, remission on therapy, remission
off therapy, relapse, and ESRD. Treatment resistance was defined as a
progressive decline in kidney function with persistence of active
urine sediment or new or persistent extrarenal manifestations of
vasculitis despite immunosuppressive treatment. Resistance to
therapy was determined after at least 1 month of therapy. Remission
was defined as the stabilization or improvement of kidney function
as measured by serum creatinine levels and resolution of hematuria
or other manifestations of systemic vasculitis for more than 1
month. The persistence of proteinuria was not considered indicative
of active glomerulonephritis. Remission off therapy was defined as
remission with no therapy or with less than 7.5 mg prednisone per
day. Relapse could only be recorded among responders (the patients
who had achieved remission either on or off therapy) and included
recurrent or new signs and symptoms of active vasculitis in any
organ.
The cohort of patients with ANCA-SVV was divided into two
groups (Figure 1): (1) patients who had reached ESRD, at or any
time after the diagnosis of ANCA-SVV, and then maintained on
chronic renal replacement therapy (ESRD group) and (2) those with
a preserved renal function (non-ESRD group). Three patients who
underwent kidney transplantation promptly after the diagnosis of
ESRD were excluded. Patients who required acute dialysis at or after
the diagnosis of ANCA-SVV, but subsequently recovered renal
function and were dialysis free as of 1 October 2007, were included
in the non-ESRD group. Conversely, patients who were dialysis
dependent at presentation and never came off were included in the
ESRD group. Dialysis dependency at presentation was considered in
cases with severe renal insufficiency requiring dialysis at, or within,
30 days of diagnosis. The start of chronic dialysis was determined as
the date when dialysis was initiated with no subsequent interrup-
tion. As our ANCA-SVV database includes information until death
or ESRD, and for the purposes of this study, a detailed supplemental
clinical information was sought from the treating nephrologists for
all cases in the ESRD group from the onset of dialysis to kidney
transplantation or death.
All patients in the ESRD group were categorized with respect to
the phase of ANCA-SVV at the point they reached ESRD. Hence,
each patient could be classified as having reached ESRD due to one
of three reasons: (1) new-onset ANCA glomerulonephritis, which
primarily includes those who presented at or near dialysis and those
patients who were treatment resistant, (2) relapse of ANCA-SVV
involving the kidney, which led to ESRD, or (3) progressive chronic
kidney disease without evidence of active ANCA glomerulonephritis
for greater than 6 months.
In cases with ANCA-SVV and ESRD, any symptoms or signs were
considered vasculitic in origin if they had been observed for a month
or more after the initiation of dialysis, to differentiate them from
uremic symptoms. We recorded all relapses of ANCA-SVV on
chronic dialysis, the organs involved, the type and duration of, and
response to, prescribed immunosuppressive therapy. Vasculitic
activity was assessed using the BVAS system.14
Infections in the ESRD group were determined as those requiring
hospitalization. For comparison of infection rates by use of
immunosuppressive therapy, a minimum of 1 month of immuno-
suppressive therapy after the onset of dialysis was required.
Malignancies were assessed by review of medical records. Death was
documented from available medical records or from the Social Security
Death index (http://ssdi.rootsweb.ancestry.com/cgi-bin/ssdi.cgi).
Statistical methods
Descriptive statistics include n, percent, mean, s.d., and IQR.
Demographics and clinical characteristics were compared between
patients who reached ESRD and those who did not reach ESRD
using Fisher’s exact tests for categorical measures and Wilcoxon rank
sum tests for continuous measures. The same tests were used to
compare clinical characteristics between subgroups of ESRD
patients. In instances where continuous measures were compared
across more than two patient groups, Kruskal–Wallis tests were used.
Incidence rates were calculated, taking into account the varying
follow-up times, and are reported as per patient-year of follow-up
using all events for relapse, infection, malignancies, and mortality.
The binomial principles were used to calculate 95% CIs and s.d. for
incidence rates. P-values for comparing two incidence rates were
calculated by testing the hypothesis that their difference was equal to
zero. Kaplan–Meier estimators were used to estimate the probability
of ESRD-free survival. Analyses were conducted using SAS 9.1
(SAS Institute, Cary, NC, USA). Exact P-values are reported with a
two-sided P-value of 0.05 or less considered statistically significant.
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